• Greenland Energy holds rights to up to 70% working interest across three onshore licenses covering more than 2 million acres in East Greenland’s Jameson Land Basin.
• Independent Sproule ERCE engineering estimates indicate recoverable oil upside of 13 billion barrels across the basin, which was extensively evaluated by ARCO decades ago but never drilled.
• The company has contracted Stampede Drilling for Arctic-rated rig services alongside agreements with Halliburton, Desgagnés, and IPT Well Solutions to support its 2026 drilling campaign.

Onshore basins of genuine scale that remain undrilled are increasingly rare. Most of the world’s major hydrocarbon-producing regions have been systematically tested over the past half-century, leaving frontier opportunities concentrated in geographies with challenging logistics, complex permitting, or historically limiting macroeconomic conditions. 

Where such basins remain, they carry a combination of technical risk and optionality that draws a specific type of investor interest. The Jameson Land Basin in East Greenland, a petroleum basin historically evaluated by US Atlantic Richfield Company (“ARCO”) but never drilled, represents one of the most prominent examples of that profile. Greenland Energy (NASDAQ: GLND) is the publicly traded platform now advancing it.

When they do emerge, these types of opportunities tend to represent outsized, binary-style outcomes where success or failure can redefine the value of an entire region.

The Jameson Land Basin Opportunity

The Jameson Land Basin covers more than 2 million acres in East Greenland and has been compared geologically to prolific hydrocarbon systems such as Prudhoe Bay in Alaska and the North Sea.

ARCO, following its discovery of the giant Prudhoe Bay oil field, invested the equivalent of more than $275 million in today’s dollars evaluating Jameson, conducting detailed field mapping, acquiring approximately 1,800 kilometers of 2D seismic data, and constructing the Constable Point Airfield that remains a key piece of regional infrastructure. Despite identifying substantial oil potential, the basin remained undrilled due to corporate strategy shifts and macroeconomic conditions rather than unfavorable technical findings.

Greenland Energy has reprocessed the legacy seismic data with modern technology, identifying more than 50 distinct oil and gas targets with structural and stratigraphic trapping potential. An independent Sproule ERCE engineering report indicates upside of 13 billion barrels of recoverable oil across the basin.

In practical terms, much of the early-stage geological risk has already been addressed, what remains is the execution risk of drilling a basin that has never been tested.

From Legacy Data to Public Market Platform

Greenland Energy was formed through the business combination of Pelican Acquisition Corporation, Greenland Exploration Limited, and March GL Company. The transaction closed March 25, 2026, with shares commencing trading on NASDAQ under the ticker symbol “GLND” the following day at an approximately $215 million implied valuation.

Under the structure, Greenland Energy holds rights to own up to 70% of three onshore licenses covering the entire petroleum basin, with working interest earned through a subsidiary of 80 Mile. ThinkEquity LLC served as financial advisor across the transaction.

The formation of a publicly traded platform provides access to capital markets at a stage where large-scale exploration programs require coordinated funding, technical execution, and long-term planning.

Operational Readiness and Partnerships

On March 27, 2026, Greenland Energy announced a five-year strategic drilling agreement with Stampede Drilling Inc. (TSX: SDI), securing Stampede’s Rig #12,  equipped for Arctic conditions, for upcoming operations in the Jameson Land Basin. Plans under the agreement call for drilling up to two wells.

The drilling contract is complemented by agreements with Halliburton for logistics planning and drilling services, Desgagnés for Arctic shipping of drilling equipment, and IPT Well Solutions as project manager providing additional oversight and technical support.

The Greenland Government has approved the mobilization and sealift landing of heavy equipment including a D9 bulldozer, trucks, excavators, loaders, generators, and housing units, which will support construction of a three-mile access road to the drilling site. A 3,500-meter-capable drilling rig has been secured for the program.

Taken together, these agreements move the project from conceptual to executable, a distinction that often defines the transition from narrative to measurable outcomes in frontier exploration.

Leadership and Capital Markets Perspective

Greenland Energy’s leadership includes Larry G. Swets, Jr. as Executive Chairman and Robert Price as Chief Executive Officer, with directors and executives drawn from the predecessor entities.

On March 26, 2026, the company appointed Joe Moglia, former Chief Executive Officer and Chairman of TD Ameritrade, as Executive Advisor to the Board. Moglia brings decades of capital markets and corporate strategy experience, including current roles as Chairman of Fundamental Global and Capital Wealth Advisors and Executive Advisor to FG Nexus.

His appointment adds a layer of capital markets perspective to a company transitioning from formation to execution.

Why the Timing Matters

Western energy security has become an explicit policy priority in recent years, with governments and capital markets increasingly focused on reducing dependence on geopolitically constrained supply sources. Greenland’s emergence as a strategic frontier aligns with that shift, and the Jameson Land Basin’s combination of scale, existing infrastructure, and regulatory progress positions Greenland Energy as an early mover in a region that has drawn attention but seen limited commercial activity.

“Our work in the Jameson Land Basin represents a rare opportunity to unlock one of the largest undrilled onshore basins in the Arctic through a disciplined, environmentally responsible approach,” said Robert Price, Chief Executive Officer of Greenland Energy.

With field activity progressing, equipment mobilization approved, and drilling partnerships in place, the company is moving toward what would be the first modern well drilled in a basin whose potential has been documented, but never tested, for more than four decades.

For more information, visit the company’s website at www.GreenlandEnergyCo.com.

NOTE TO INVESTORS: The latest news and updates relating to GLND are available in the company’s newsroom at ibn.fm/GLND

Disseminated on behalf of Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF)and may include paid advertising.

• Planet Ventures provides shareholders with exposure to private space and aerospace companies through a publicly traded investment vehicle.
• The company employs a diversified portfolio strategy spanning infrastructure, software, energy, robotics, and emerging space applications.
• Its investment approach is positioned to benefit from the continued growth and commercialization of the global space sector.
• Recent activity includes investments in Relativity Space (via MCXGP), Antaris following its $28 million Series A financing, and General Astronautics, a Y Combinator Winter 2026 company.
• The company has also deployed capital into early-stage opportunities such as Mantis Space and GRU Space, reflecting a focus on emerging technologies across the space economy.

Planet Ventures (CSE: PXI) (OTC: PNXPF) is an investment issuer focused on identifying and investing in innovative companies operating within the space and aerospace sectors. The company’s strategy is centered on providing shareholders with exposure to emerging, high-growth opportunities, including private companies that are typically accessible primarily to venture capital and institutional investors.

The company employs a portfolio-driven investment approach, seeking to build a diversified base of investments across multiple segments of the space economy. Its activities are focused on sourcing and participating in opportunities globally, leveraging its network and experience to access and evaluate potential investments aligned with long-term growth trends in the sector.

Planet Ventures aims to create shareholder value through strategic capital allocation into companies developing technologies and services that support the expanding commercial space ecosystem.

The company is headquartered in Vancouver, British Columbia.

Portfolio

Planet Ventures operates as an investment platform, deploying capital into companies across the space and aerospace value chain, including infrastructure, software, energy, robotics, and emerging applications.

The company’s investment thesis is based on the view that many of the most significant opportunities in the space sector remain private and are not directly accessible to public market investors. Through its investment approach, Planet Ventures provides shareholders with indirect exposure to these companies, including through positions that may offer access to private businesses typically only available to venture capital and institutional investors.

Launch & Infrastructure

Planet Ventures has gained exposure to Relativity Space Inc. through an investment in MCXGP Relativity Fund I LLC, a special purpose vehicle that participated in the company’s most recent financing round. Relativity Space is developing reusable launch vehicles, including the Terran R rocket, designed for mid-to-heavy lift missions and low Earth orbit satellite deployment.

The company has also invested in Mantis Space Corp., which is developing orbital energy infrastructure intended to deliver power to satellites and other space-based systems.

Software & Data Platforms

Planet Ventures has made a strategic investment in Antaris Inc., an AI-powered platform designed to support the design, simulation, and operation of satellite constellations. The platform is intended to streamline mission development and enable software-driven approaches to space operations.

Emerging Applications & Robotics

Planet Ventures has invested in Galactic Resource Utilization Space Inc. (“GRU Space”), a company focused on developing habitat infrastructure for use beyond Earth, including concepts related to space tourism.

The company has also invested in General Astronautics, a space robotics company developing autonomous systems designed to operate in microgravity environments to support research and manufacturing activities in space.

Market Opportunity

Planet Ventures operates within the global space economy, which is valued at approximately $626 billion in 2025 and is projected to exceed $1.8 trillion by 2035, according to data from the World Economic Forum. Growth in the sector is being driven by increasing commercialization (with commercial revenues accounting for 78% of the total market, according to the Space Foundation), as well as expanding satellite applications, infrastructure development, and national security initiatives.

The space economy encompasses a wide range of activities that can be broadly divided into upstream and downstream segments. Upstream activities include launch systems, satellite manufacturing, and on-orbit operations, while downstream activities include satellite communications, navigation and positioning services, and earth observation.

The satellite segment represents a significant portion of the overall market, alongside growing areas such as space infrastructure, software platforms, and emerging commercial applications. Increased participation from private companies continues to play a central role in the expansion of the sector.

Leadership Team

Etienne Moshevich, Chief Executive Officer, has a background in capital markets and private investing and has focused on evaluating, financing, and advising early-stage and growth companies across multiple sectors. His role includes portfolio strategy, capital allocation, and investor relations, with a focus on aligning management teams and shareholders toward long-term outcomes.

Desmond Balakrishnan, Executive Director, is a partner at McMillan LLP and an experienced capital markets and securities lawyer. He has advised clients across multiple industries and has experience in private equity investments, public offerings, mergers and acquisitions, and listed company advisory.

Brian Shin, Chief Financial Officer, specializes in financial reporting, corporate finance, auditing, corporate strategy, and risk management. He provides accounting and consulting services to both public and private companies and has served as CFO for multiple organizations in Canada.

For more information, visit the company’s website at https://planetventuresinc.com.

NOTE TO INVESTORS: The latest news and updates relating to PNXPF are available in the company’s newsroom at https://ibn.fm/PNXPF

• Designations from established global organizations such as the European Commission carry meaningful implications for biotechnology companies.
• Soligenix announced that the European Commission granted orphan drug designation to SGX945 for the treatment of Behçet’s disease.
• SGX945 is based on dusquetide, a synthetic peptide belonging to a class of compounds known as innate defense regulators.

Recognition from global regulatory authorities can serve as a powerful validation of a therapy’s potential, particularly in the rare disease space where development challenges are significant and patient needs are urgent. Soligenix (NASDAQ: SNGX) has secured that type of validation, as the European Commission granted orphan drug designation to its investigational therapy SGX945 for the treatment of Behçet’s disease, reinforcing both the promise of the therapy and the company’s broader development strategy.

Designations from established global organizations such as the European Commission carry meaningful implications for biotechnology companies. Orphan drug designation in the European Union (“EU”) is specifically intended to encourage the development of treatments for rare diseases, which are defined as conditions affecting no more than five in 10,000 people in the EU. These designations provide important incentives, including protocol assistance, reduced regulatory fees and up to 10 years of market exclusivity following approval, all of which are designed to support the advancement of therapies that might otherwise face significant development barriers.

Such recognition also signals that a therapy addresses a condition with a high unmet medical need and demonstrates the potential to provide meaningful clinical benefit. The European Medicines Agency notes that orphan designation is granted when a product is intended to diagnose, prevent or treat a life-threatening or chronically debilitating condition and where existing treatment options are limited or inadequate. For companies such as Soligenix, this type of validation can help accelerate development, attract investment and enhance visibility within the global healthcare community.

The condition targeted by SGX945, Behçet’s disease, is a rare and chronic inflammatory disorder characterized by inflammation of blood vessels throughout the body. Behçet’s disease can cause recurring symptoms such as painful oral and genital ulcers, skin lesions and inflammation affecting multiple organ systems, and it may lead to serious complications depending on the organs involved. The disease is often relapsing in nature and can significantly impact quality of life, underscoring the need for effective and well-tolerated treatment options.

Against this backdrop, Soligenix announced that the European Commission, acting on a positive recommendation from the European Medicines Agency’s Committee for Orphan Medicinal Products, granted orphan drug designation to SGX945 (dusquetide) for the treatment of Behçet’s disease. This designation represents a key milestone in the development of the therapy and aligns with the company’s focus on addressing rare and difficult-to-treat conditions.

SGX945 is based on dusquetide, a synthetic peptide belonging to a class of compounds known as innate defense regulators. These molecules are designed to modulate the body’s immune response, promoting an anti-inflammatory and tissue-healing profile while enhancing the body’s ability to respond to infection. This mechanism represents a novel therapeutic approach for inflammatory and immune-mediated diseases, including Behçet’s Disease, where dysregulated immune activity plays a central role.

Orphan drug designation in the European Union provides a range of development and commercial advantages. These include eligibility for protocol assistance from the European Medicines Agency, access to centralized marketing authorization procedures and a 10-year period of market exclusivity upon approval, all of which are intended to support the successful development and commercialization of therapies for rare conditions.

In addition to its regulatory benefits, the designation reinforces the clinical rationale for SGX945. The therapy has demonstrated encouraging results in earlier studies, including improvements in oral ulcer outcomes among patients with Behçet’s disease and a favorable tolerability profile. These findings support continued development and suggest that the therapy may offer a meaningful alternative to existing treatment approaches.

The importance of SGX945 extends beyond a single indication. As part of Soligenix’s broader pipeline, the therapy reflects a platform-based approach that seeks to leverage scientific expertise across multiple programs targeting rare inflammatory and immune-related conditions. This strategy enables the company to pursue a range of therapeutic opportunities while maintaining a focused development framework.

The European Commission’s decision to grant orphan drug designation to SGX945 represents a meaningful step forward in that effort. By providing both regulatory support and commercial incentives, the designation helps position the therapy for continued advancement while highlighting its potential to address a significant unmet medical need. For patients living with Behçet’s Disease, where treatment options remain limited, such progress offers the possibility of improved outcomes and a better quality of life.

As Soligenix continues to advance its clinical programs, milestones such as this underscore the importance of collaboration between biotechnology innovators and global regulatory authorities. Together, these efforts play a critical role in bringing new therapies to patients with rare and challenging conditions, while reinforcing the value of scientific innovation in addressing unmet medical needs.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• Targeted cancer therapies are increasingly being paired with immunotherapy and chemotherapy to improve outcomes across multiple tumor types
• First-in-class PP2A inhibitor LB-100 is designed to enhance treatment response by disrupting cancer cell repair mechanisms and boosting immune activity
• Ongoing clinical trials are exploring LB-100 across solid tumors, including ovarian and colorectal cancers, where unmet need remains high

Cancer treatment is entering a phase where the question is no longer which single therapy works best, but how treatments can be combined to improve outcomes. Across oncology, resistance and relapse remain persistent challenges, and the industry’s response has been increasingly clear: multi-drug regimens targeting different biological pathways are delivering results that single agents cannot.

Lixte Biotechnology Holdings Inc. (NASDAQ: LIXT) is advancing a first-in-class compound designed to fit directly into that model. Rather than developing a standalone therapy, the company is focused on enhancing the effectiveness of existing treatments, specifically chemotherapy and immunotherapy, across a broader range of patients.

The Case for Combination Oncology

The shift toward combination-based treatment reflects a fundamental biological reality. Cancer cells are highly adaptive. Therapies that target a single pathway often lose effectiveness as tumors evolve alternative survival mechanisms.

The industry response has been to combine therapies that act through different mechanisms simultaneously. This approach is gaining traction as clinical data continues to show improved response rates and durability when targeted therapies are paired with immunotherapy or traditional chemotherapy.

The pattern is consistent: treatments that both damage cancer cells directly and activate the immune system tend to outperform either strategy alone. Lixte’s development strategy is built around that premise.

How LB-100 Fits the Model

LB-100 is a small molecule inhibitor of protein phosphatase 2A (“PP2A”), an enzyme involved in regulating key cellular functions, including DNA repair. By inhibiting PP2A, the compound disrupts the ability of cancer cells to recover from treatment-induced damage, increasing their susceptibility to chemotherapy and radiation.

At the same time, LB-100 has demonstrated immune-related activity. It promotes cytokine production, increases T-cell proliferation, and enhances the generation of neoantigens, helping the immune system better recognize and attack tumor cells.

This dual mechanism positions LB-100 as a complementary agent within combination regimens, particularly alongside immune checkpoint inhibitors such as PD-1 therapies.

Supporting the biological rationale, external research has shown that tumors with PP2A-related mutations may respond more favorably to immunotherapy, reinforcing the potential role of PP2A inhibition in enhancing immune response.

Clinical Development Across High-Need Indications

Lixte is advancing LB-100 across multiple clinical programs focused on solid tumors with limited treatment options.

In ovarian clear cell carcinoma, the compound is being evaluated in combination with a PD-1 inhibitor in a Phase 1b/2 study, with patient enrollment ongoing. Additional trials are exploring LB-100 in metastatic microsatellite-stable colorectal cancer, a setting where traditional immunotherapy has historically shown limited effectiveness.

The company has also completed Phase 1b enrollment in a study combining LB-100 with chemotherapy in advanced soft tissue sarcoma, with data analysis underway. This represents a potential near-term catalyst as the first meaningful readout from its combination strategy in that indication.

Preclinical research, supported by more than 25 published studies, has demonstrated anti-cancer activity across multiple tumor types, while early-stage clinical trials have established a favorable safety profile without significant increases in toxicity when used alongside standard treatments.

Addressing the Limits of Current Therapies

The rationale for a treatment enhancer like LB-100 is rooted in the limitations of existing therapies. Chemotherapy and immunotherapy both face challenges, including resistance, inconsistent response rates, and toxicity constraints that limit dosing.

A compound capable of increasing tumor sensitivity while also improving immune system engagement addresses those challenges directly. Rather than replacing established therapies, the goal is to improve how effectively they work.

This approach also aligns with growing focus on the tumor microenvironment, where immune activation is increasingly viewed as a critical factor in long-term outcomes.

Positioned Within an Evolving Treatment Landscape

As oncology continues to move toward personalized, multi-drug treatment strategies, the role of complementary therapies is expanding. Companies developing agents that enhance existing treatments, rather than competing with them, are becoming an important part of that ecosystem.

Lixte’s focus on PP2A inhibition, supported by ongoing clinical development and a defined patent portfolio, reflects that positioning.

The company’s long-term opportunity is tied to the success of combination oncology itself. If multi-drug regimens continue to define the next generation of cancer treatment, therapies designed to amplify existing standards of care may play a meaningful role in improving patient outcomes.

For more information, visit the company website at https://lixte.com.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

Disseminated on behalf of  Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.

• Central bank gold buying has been unfolding against an international scenario that continues to favor safe-haven assets.
• Lahontan is working to build value through continued drilling, metallurgical work and project advancement.
• The company is showing a steady stream of updates this year, including drilling and key financing.

Gold’s appeal rarely rests on a single catalyst, and the current environment is no exception. Rising geopolitical tension, stubborn inflation risk, elevated sovereign debt and continued official-sector buying are all feeding the case for a renewed gold cycle, a backdrop that helps explain why Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) is drawing attention as it advances four gold and silver properties in Nevada’s Walker Lane, including its flagship Santa Fe Mine project

One reason the gold story still has momentum is that central banks have not meaningfully stepped away from the market. The World Gold Council reports that net central-bank demand reached 863 tonnes in 2025, far above the 2010–2021 annual average of 473 tonnes, and its broader 2025 Gold Demand Trends report notes that total gold demand topped 5,000 tonnes for the first time. That matters because it shows official buyers remained active even as prices reached record highs, reinforcing the view that gold is being treated not simply as a trade but as a strategic reserve asset.

The motivations behind that buying are also becoming clearer. In its 2025 Central Bank Gold Reserves Survey, the World Gold Council said central banks continued to rank economic and geopolitical factors highly in reserve-management decisions, with respondents citing inflation concerns, geopolitical instability, gold’s performance during crises and its diversification benefits. The same survey found that 76% of respondents believe gold will represent a higher share of total reserves five years from now, while 73% expect the U.S. dollar’s share of reserves to be lower. More recently, the council reported that central banks bought a net 27 tonnes in February 2026 and highlighted a growing number of African central banks turning to gold as a strategic diversification tool.

That official buying has been unfolding against an international scenario that continues to favor safe-haven assets. The IMF’s April 2026 World Economic Outlook says the global economy is now facing a major test from war in the Middle East and projects slower growth with somewhat higher headline inflation in 2026. In a related IMF blog post, the fund said that, whether the conflict is short or prolonged, the likely channels point toward higher prices and slower growth.

That mix of geopolitical instability and inflation risk matters because it revives two of gold’s oldest use cases at once: wealth preservation and insurance. The IMF’s press briefing on the April 2026 outlook said higher commodity prices are a classic negative supply shock that can raise costs, disrupt supply chains and erode purchasing power. Meanwhile, the IMF has also emphasized that debt burdens remain historically elevated, projecting global public debt would rise above 100% of GDP by 2029. A Finance & Development article reported that global public debt climbed to 93.9% of GDP in 2025 and is on track to breach 100% by 2028. When markets are asked to absorb war risk, inflation risk and debt risk at the same time, gold tends to stay part of the conversation

That is the macro setting in which Lahontan, a Canadian mine development and mineral exploration company with four top-tier properties in Nevada, is working to build value through continued drilling, metallurgical work and project advancement. The company’s Santa Fe project is a past-producing heap-leach operation with a sizeable current resource base. A National Instrument 43-101 compliant indicated resource of 1.539 million ounces gold equivalent and an inferred resource of 411,000 ounces gold equivalent, all pit constrained. Lahontan also says Santa Fe produced 356,000 ounces of gold and 784,000 ounces of silver between 1988 and 1995 through open-pit heap-leach mining.

Recent company activity shows the story is moving forward. Lahontan’s investor page shows a steady stream of 2026 updates, including metallurgical work, drilling and financing. The company also reported that it had mobilized a second drill rig to Santa Fe to augment ongoing drilling, with Executive Chair, President and CEO Kimberly Ann stating, “Since the company’s inception, Lahontan drilling has focused on resource definition and expansion to support our goal of resuming gold and silver production and mining operations at Santa Fe.” In February, the company also reported 36.6 meters grading 3.11 g/t gold equivalent from surface at West Santa Fe, including 10.7 meters grading 5.75 g/t gold equivalent, results that support shallow oxide mineralization with heap-leach potential.

The company has also been working to improve the technical case around recoveries and funding. Lahontan’s investor materials note an April 13, 2026, update reports cyanide recoveries of 81% for gold and 60% for silver at West Santa Fe, while the company also closed the final tranche of a private placement for aggregate proceeds of $13.6 million earlier this month. Earlier this year, Lahontan selected RESPEC and Kappes Cassiday to update the Santa Fe mineral resource estimate and PEA, a step that could prove meaningful in a stronger gold-price environment.

While there is no guarantee of success in the gold development space, Lahontan’s broader setup is hard to ignore. Central banks are still buying, governments are still diversifying reserves, war is still feeding safe-haven demand, and inflation and debt remain difficult to dismiss. For companies able to advance credible Nevada gold projects in that scenario, the market may be more willing to pay attention. Lahontan is focused on making that case with drilling, updated studies, metallurgical data and capital raises that keep Santa Fe and its surrounding properties moving ahead.

For more information, visit the company’s website at www.LahontanGoldCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to LGCXF are available in the company’s newsroom at ibn.fm/LGCXF

Disseminated on behalf of  ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF)and may include paid advertising.

• Canadian near-term precious metal producer ESGold is advancing toward the May start of a drill program expected to further define priority targets on its 20,618-hectare Montauban Gold-Silver Project in Quebec
• The company is simultaneously working to construct a fully permitted mill on site and expand the scope of its exploration
• ESGold is employing a low CapEx strategy that includes funding from a private placement initiative and an agreement with Ocean Partners UK Ltd. that provides a credit facility and a dedicated buyer of gold and silver produced from its planned tailings cleanup operation
• Despite market fluctuations, gold has effectively doubled in value since January 2025 and is expected to remain at near-record levels in the coming months, benefiting companies positioned to provide supply for continued demand

Clean process near-term gold and silver production company ESGold (CSE: ESAU) (OTCQB: ESAUF) is completing preparations for anticipated drilling operations in May at its Montauban Gold-Silver Project in Quebec while simultaneously progressing toward mill construction and an expanded exploration footprint. 

“We are fully funded to execute on this plan, and our focus is on disciplined execution across both development and exploration as we move through what we believe will be a very important period for the company,” ESGold CEO Gordon Robb stated in a news release earlier this month (https://ibn.fm/07Mcq).

ESGold is employing a tailings-cleanup-to-cash-flow model to generate revenues that can then be reinvested in the company’s operations, paving the way for new exploration at the site. 

“We are fully permitted for a thousand-ton-per-day [mill] operation. We’re fully funded to build the thousand-ton-per-day facility and we will be generating revenue to fund further exploration and development of the past-producing Montauban asset,” Robb added during an interview at the March Swiss Mining Institute (“SMI”) conference in Switzerland with conference Chairman Carlos Vargas (https://ibn.fm/o0odT).

“We have material sitting on surface. … If we can extract that economic value while cleaning up these tailings, it puts us in a very enviable position to be generating cash flow,” he added. “We have equipment arriving onsite. That building is complete. … We’re looking to be cash-flowing by the year-end.”

ESGold inked a C$9 million binding term sheet with Ocean Partners UK Ltd. last year that provides a credit facility to the company, while Ocean Partners buys the gold and silver dore produced from Montauban tailings and crown pillar material. The company had access to the first C$3 million tranche in February, while the remaining C$6 million will be available in a second tranche approximately five months before Phase 2 production, which is currently expected to begin next March. 

The targeted drill program will test zones identified as high potential areas by ESGold’s expanded Ambient Noise Tomography (“ANT”) imaging as well as data from historical drilling and detailed structural interpretation. 

“This is a past-producing asset that was never properly explored,” Robb said in the SMI interview. “The deepest drill hole went down to about 200 meters at depth. It was never drilled to the north [or] the south. We wanted to get a better idea of what we’re looking at, so we did an ANT survey coupled with a VTEM (Versatile Time Domain Electromagnetic) survey and we put together a 3-D model. … What we saw was something a lot bigger than originally anticipated. We found structure down to 900 meters at depth to the strike that looked [at least] 2 kilometers at length. It really excited our geologists and gave us a lot of targets.”

The program aims to determine if the mineralized corridor continues across the broader land package and to further define the scale and structural framework of the Montauban system, which spans 417 mining claims and 20,618 contiguous hectares (about 50,948 acres) across the Montauban and Chavigny townships west of Quebec City (https://ibn.fm/c2bvN).

“[The mill construction, ANT survey and drill program] are foundational steps, and they are all advancing at the same time. What is particularly exciting is how these initiatives come together. We are moving toward production while, in parallel, expanding our understanding of what we believe could be a much larger system,” Robb stated in the news release. 

Gold has enjoyed a massive surge in spot value since the beginning of the current U.S. administration, and while recent market fluctuations have brought gold back from its record peak in March the precious metal continues to enjoy a price level nearly double where it was in January 2025, creating optimism for gold sector producers positioned to provide supply for demand.

For more information, visit the company’s website at https://esgold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

• Soligenix reports clinical update centered on cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma that primarily affects the skin.
• The interim update highlighted that the overall blinded aggregate response rate observed in patients who have completed treatment remains consistent with prior reporting.
• In addition, the company reported positive results from a study evaluating HyBryte(TM) against Valchlor(R), an existing treatment option for cutaneous T-cell lymphoma.

Advancing clinical research while generating positive data is a critical combination in biotechnology, particularly when addressing diseases with limited treatment options. Soligenix (NASDAQ: SNGX) is demonstrating that momentum as it provides  both an encouraging clinical update from its phase 3 FLASH2 study and positive comparative clinical results for its HyBryte therapy, reinforcing the company’s focus on developing innovative treatments for serious conditions.

The research highlighted in these announcements centers on cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma that primarily affects the skin. According to the National Cancer Institute, CTCL can cause persistent skin lesions, plaques and tumors, often leading to significant discomfort and reduced quality of life. The disease is typically chronic and may require long-term treatment, making the development of effective and well-tolerated therapies particularly important.

Treatment options for CTCL remain limited, especially in early-stage disease where therapies are often used off-label or associated with notable side effects. The American Cancer Society notes that treatments such as phototherapy, topical therapies and systemic approaches are commonly used to manage symptoms of CTCL, although their effectiveness can vary and may not provide durable responses for all patients. In addition, some of these therapies carry risks with prolonged use, including skin irritation, damage and an increased risk of secondary skin cancers, underscoring the need for safer and more targeted treatment options.

The burden of the disease extends beyond physical symptoms. Chronic skin involvement, visible lesions and recurring flares can have a meaningful impact on quality of life, affecting both physical comfort and emotional well-being. As a result, ongoing research into therapies that can provide sustained efficacy with improved tolerability is considered a priority within the oncology and dermatology communities.

Against this backdrop, Soligenix has reported progress across two recent developments involving HyBryte, its investigational photodynamic therapy for CTCL. The company is continuing its phase 3 FLASH2 clinical trial, with an interim analysis expected in the second quarter of 2026 and topline results anticipated in the second half of the year. This late-stage study is designed to further evaluate the safety and efficacy of HyBryte following earlier clinical success.

The clinical update also highlighted that the overall blinded aggregate response rate observed in patients who have completed treatment remains consistent with prior reporting at approximately 48%, compared to a 25% response rate used to design the study. This difference is significant because it suggests that the therapy may be performing above initial expectations; final conclusions will depend on the unblinded data and full study results.

In addition, Soligenix reported positive results from a comparative study evaluating HyBryte against Valchlor, an existing treatment option for CTCL. The study measured outcomes over a 12-week treatment period and focused on defined improvements in disease severity.

According to the reported data, 60% of patients treated with HyBryte achieved the defined level of treatment success, compared to 20% of patients treated with Valchlor. The average cumulative improvement in disease severity scores was 52.5% in the HyBryte group compared to 34.7% in the Valchlor group, indicating a potentially stronger treatment effect.

The safety profile observed in the study further differentiates the therapy. HyBryte was reported to be well tolerated among treated patients, while a portion of patients receiving Valchlor experienced treatment-related adverse events, including skin reactions such as dermatitis and sensitivity at the application site. These findings are important because tolerability is a key consideration in chronic conditions that require ongoing treatment.

HyBryte is based on a photodynamic therapy approach that combines a light-activated compound with controlled exposure to visible light. This mechanism allows for targeted treatment of affected skin areas while minimizing systemic exposure, which may contribute to its favorable safety profile.

Together, the Phase 3 clinical update and comparative study results provide a clearer picture of HyBryte’s potential role in the treatment landscape for CTCL. The combination of encouraging efficacy signals and a favorable tolerability profile suggests that the therapy could address some of the limitations associated with existing treatments, particularly if these findings are confirmed in larger studies.

As Soligenix continues to advance its clinical programs, the data emerging from these studies highlight the importance of sustained research and innovation in rare and challenging diseases. With additional clinical milestones expected in 2026, the company’s progress reflects both the complexity of drug development and the potential impact of new therapeutic approaches on patient care.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• Oncotelic Therapeutics has recently entered a strategic partnership with TechForce Robotics to commercialize a PDAOAI-enhanced, GMP-compliant robotics platform
• The collaboration integrates AI-driven compliance systems with advanced robotics for pharmaceutical manufacturing automation
• This pivot underscores a broader strategy: extending Oncotelic’s AI capabilities beyond therapeutics into scalable, high-value industrial applications

Oncotelic Therapeutics (OTCQB: OTLC) is signaling a significant strategic evolution, moving beyond its roots as a clinical-stage biotechnology company into the quickly expanding intersection of artificial intelligence and industrial automation. Through two closely aligned announcements, the firm has unveiled a strategic partnership with TechForce Robotics, which positions it to commercialize a next-generation, AI-enhanced platform created for regulated pharmaceutical environments (ibn.fm/aA1Bt).

At the core of this pivot is Oncotelic’s proprietary PDAOAI platform, an AI-driven system designed to improve compliance, monitoring, and operational intelligence. By integrating this innovation with TechForce Robotics’ hardware and manufacturing expertise, the companies aim to deliver a GMP-compliant robotics solution capable of automating critical workflows in pharmaceutical production and laboratory settings.

The newly announced platform is already deployed within strict GMP (Good Manufacturing Practice) environments and is currently addressing one of the most common challenges in biopharma manufacturing: maintaining regulatory compliance while scaling production. Through automated material handling, real-time monitoring, and AI-enabled deviation detection, the system is expected to cut down on human intervention, reduce contamination risks, and improve process consistency.

OTLC’s partnership with TechForce formalizes this effort through a joint development, manufacturing, and licensing agreement, creating a structured pathway toward commercialization. This isn’t just a research collaboration; it represents a coordinated go-to-market strategy aimed at deploying a scalable, intelligent automation system across pharmaceutical and potentially adjacent regulated industries (ibn.fm/zymOX).

From the perspective of an investor, this shift is particularly noteworthy. While Oncotelic continues to advance its therapeutic pipeline, including TGF-beta-focused treatments targeting orphan diseases and high unmet medical needs, the integration of AI and robotics introduces a parallel revenue pathway that is less dependent on the long timelines and binary risks associated with drug development.

This strategic rationale becomes even clearer when viewed against broader industry dynamics. Pharmaceutical manufacturers are under increasing pressure to improve efficiency, ensure compliance, and reduce reliance on manual processes. AI-enhanced automation is emerging as a critical solution layer, and Oncotelic’s PDAOAI platform is designed specifically to address these needs through data-driven, intelligent workflows.

The complementary nature of the partnership is central to its potential success. TechForce Robotics contributes advanced engineering, scalable manufacturing, and capabilities and deployment infrastructure, while Oncotelic provides domain expertise in biotechnology and AI-enhanced pharmaceutical processes. This alignment enables the combined platform to move more rapidly from concept to commercialization, speeding up time-to-market in a sector where demand for automation is growing (ibn.fm/raqL2).

Leadership also plays a critical role in underpinning this initiative. CEO, Dr. Vuong Trieu, brings decades of experience across oncology, drug development, and AI applications in healthcare, strategically positioning Oncotelic to bridge the gap between scientific innovation and industrial implementation. His background strengthens the company’s ability to translate complex biomedical and regulatory requirements into scalable technology solutions.

Importantly, the transition does not represent a departure from Oncotelic’s core mission but rather an expansion of it. By leveraging its AI capabilities beyond therapeutics, the company is creating a broader innovation platform that spans both drug development and the needed infrastructure required to manufacture those therapies efficiently and compliantly.

For investors, Oncotelic Therapeutics now represents a dual opportunity: exposure to a clinical-stage biotech pipeline alongside a scalable, AI-driven automation platform aimed at high-demand industrial use cases. This strategic diversification could enhance long-term value creation while mitigating some of the inherent risks associated with traditional biotech development cycles.

For more information, visit the company’s website at www.Oncotelic.com.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC

• American Fusion(TM) used the 2026 ARPA-E Energy Innovation Summit to advance its commercial strategy and expand relationships across the fusion ecosystem.
• The company is developing innovational decentralized fusion technologies through its wholly owned subsidiary, Kepler Fusion Technologies, centered on the Texatron(TM) platform, targeting data center operators and developers as an initial customer base for future power deployment.
• American Fusion(TM) is pursuing supply chain relationships for key fusion inputs including helium-3 and deuterium and is also evaluating a potential Frankfurt Stock Exchange listing as part of a broader capital markets strategy.

American Fusion(TM) (OTC: AMFN), a developer of next-generation fusion energy technologies, is seeking to establish its place within the increasingly competitive fusion energy sector by sharpening its commercialization strategy, building institutional relationships, and refining its long-term market positioning.

The company, which recently rebranded from Renewal Fuels following its merger with Kepler Fusion Technologies, participated in the 2026 ARPA-E Energy Innovation Summit, a U.S. Department of Energy-backed gathering widely viewed as one of the most prominent annual forums for emerging energy technologies (https://ibn.fm/k5sD0).

According to a company news release, the summit provided American Fusion(TM) an opportunity to engage directly with government stakeholders, technical institutions, investors and other fusion developers while assessing the sector’s evolving competitive landscape.

Fusion energy has drawn growing public and private investment in recent years as governments and corporations search for long-term clean energy alternatives capable of delivering reliable baseload electricity. The sector includes well-funded private developers such as Commonwealth Fusion Systems, Helion Energy and TAE Technologies, all of which were represented at the ARPA-E summit. While most fusion companies remain in developmental stages, competition has intensified around which technologies may ultimately prove commercially viable.

American Fusion(TM) is pursuing a strategy built around its Texatron(TM) fusion platform, an aneutronic fusion design under development by Kepler Fusion Technologies. Management describes the system as focusing on compact and modular architecture, direct energy conversion, and scalable deployment for industrial and infrastructure applications. Although the technology remains under development, the company is working to differentiate itself by emphasizing deployment flexibility and infrastructure-focused applications rather than solely long-term utility-scale grid replacement.

At the ARPA-E summit, American Fusion(TM) said it held meetings with multiple U.S. government and research organizations, including representatives from the U.S. Navy, Naval Nuclear Laboratory and Naval Research Laboratory. The company also met with Department of Energy officials, national laboratories and university partners as it seeks to broaden technical collaboration and potential funding opportunities.

American Fusion(TM) additionally reported evaluating public-private financing opportunities and strategic partnerships that may support long-term development. While no funding agreements were announced, the company’s participation reflects a broader trend across the fusion sector, where many early-stage developers are seeking to pair private capital with government-backed innovation support.

One of the clearest developments from the summit was the company’s articulation of its first commercial target market. American Fusion(TM) said it has identified data center developers and operators as an initial target customer segment, particularly those requiring behind-the-meter power solutions and long-term electricity agreements.

The rationale reflects rising global electricity demand tied to artificial intelligence, cloud computing and next-generation data infrastructure. Data centers increasingly require dense, uninterrupted power supply, and many operators are exploring alternative generation methods as grid constraints and electricity demand rise. Management believes fusion-based systems, if successfully commercialized, could eventually provide high-density on-site power generation for such facilities.

Chief Executive Richard Hawkins noted that reliable and affordable electricity is becoming a central issue across computing infrastructure, particularly as operators seek secure power sources for energy-intensive facilities. “Securing the underlying components and inputs required to support that delivery is not straightforward. This is not an easy supply chain to establish at scale, and the progress we are making across commercial strategy and supply chain development represents a meaningful step forward,” Hawkins said.

Alongside commercial planning, American Fusion(TM) is also evaluating long-term supply chain requirements needed to support eventual deployment. That includes sourcing of fusion fuel inputs such as helium-3 and deuterium, materials critical to the company’s intended fusion process. Management has indicated that establishing dependable access to those materials will be an important part of long-term scaling efforts.

To support that strategy, the company is considering a potential dual listing on the Frankfurt Stock Exchange, which management believes could improve access to European capital markets and strengthen alignment with international suppliers and industrial partners. The company has also noted that certain helium-3 sourcing opportunities may be more accessible through European-linked supply channels, though no definitive agreements have yet been announced.

“As we move from development toward execution, establishing the right supply chain relationships becomes increasingly important,” said Brent Nelson, CEO of Kepler Fusion Technologies. “Access to reliable inputs and alignment with the right partners will be key to supporting long-term deployment.”

For more information, visit the company’s website at www.AmericanFusionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to AMFN are available in the company’s newsroom at https://ibn.fm/AMFN

• Frontieras notes milestone moment: groundbreaking of facility based on a new industrial model built on extracting the full value of coal.
• The company’s proprietary approach reframes coal as a versatile raw material capable of producing a wide spectrum of outputs through controlled processing.
• At the core of this strategy is Frontieras’s FASForm(TM) process, a solid carbon fractionation technology that separates coal into its constituent components.

Recent geopolitical conflict and supply disruptions have underscored how vulnerable global energy systems remain, with oil markets particularly exposed to shocks that can ripple through economies and industries almost instantly. The current situation has renewed the urgency of finding new approaches to domestic, feedstock-driven energy production are gaining urgency. Frontieras North America is advancing one such model through its proprietary technology that transforms coal into fuels, hydrogen and industrial products, positioning the resource as a strategic alternative in a constrained energy environment.

“On February 28, the United States and Israel launched strikes on Iran,” a recent Frontieras release, written by CEO Matt McKean, states. “Within days, the Strait of Hormuz was closed. Twenty percent of the world’s seaborne oil disappeared from the market overnight. Brent crude blew past $120 a barrel. Diesel prices across America surged more than 50% year over year. Fertilizer markets seized. Nations began rationing fuel. The International Energy Agency called it the largest supply disruption in the history of the global oil market.

“That phrase is worth sitting with,” McKean continued. “Not the largest disruption in a decade. Not the largest since the Gulf War. The largest in history.”

McKean goes on to focus on a key milestone for the company: the physical and strategic groundwork being laid for its first commercial-scale facility. The company broke ground on the facility this month, with McKean noting that “we’re not just breaking ground on a project, we’re breaking ground on an industry”—framing the moment as the beginning of a new industrial model built on extracting the full value of coal. 

According to Frontieras, traditional coal use has long focused on a single outcome: burning it for heat or electricity. This approach leaves much of coal’s inherent chemical and economic value untapped. The company’s proprietary approach reframes coal as a versatile raw material capable of producing a wide spectrum of outputs through controlled processing.

At the core of this strategy is Frontieras’s FASForm(TM) process, which the company describes as a solid carbon fractionation technology that separates coal into its constituent components. “What Frontieras is building in Mason County is not a coal mine,” McKean explains. “It is not a power plant. It is not a refinery in the traditional sense. 

“It is the first commercial-scale deployment of FASForm Solid Carbon Fractionation, a patented, zero-waste process that takes coal and disassembles it at the molecular level into multiple higher-value products: ultra-low sulfur diesel, naphtha, purified solid carbon fuel, hydrogen, ammonium sulfate fertilizer, and industrial chemicals,” he continued. “No combustion. No emissions from the process itself. Six product streams from a single feedstock, produced entirely from American resources on American soil.”

This process produces liquid fuels such as diesel, jet fuel and naphtha, as well as hydrogen and a purified carbon product. The company emphasizes that these outputs are generated in a continuous process designed to maximize yield and eliminate waste streams, positioning coal as a multiproduct industrial input rather than a single-use fuel. This capability allows one feedstock to support multiple markets simultaneously, including transportation fuels, industrial gases and materials.

This strategic approach treats coal not as a declining or problematic resource but as an underutilized one. Frontieras’s model is built on unlocking what coal already contains rather than compensating for its limitations. This perspective aligns with broader data on global reserves. According to the U.S. Energy Information Administration, proven recoverable coal reserves total about 1.16 trillion short tons worldwide, underscoring the scale and longevity of the resource. By applying a process that extracts multiple outputs from each ton, the company is effectively increasing the economic value of existing reserves without requiring new feedstocks.

The recent Frontieras report also notes the infrastructure implications of this model. Frontieras is not building isolated facilities but is designing its systems to integrate with existing coal supply chains and energy infrastructure. The company describes how its technology can be deployed in regions with established mining operations, transportation networks and industrial demand, allowing those ecosystems to evolve rather than be replaced. This approach reflects a broader industrial strategy in which legacy assets are reconfigured into higher-value production hubs rather than phased out.

A central theme of Frontieras is scale. The company outlines its plan to develop large, commercially viable facilities capable of processing thousands of tons of coal per day. These plants are designed to operate continuously and generate multiple revenue streams from a single input, which the company positions as a key differentiator. The ability to produce fuels, hydrogen and carbon products simultaneously would allow each facility to serve multiple markets, reducing reliance on any single commodity cycle and improving overall economic resilience.

Frontieras also connects its work to the growing demands of modern industry. The report points to the rising need for consistent, high-density energy and industrial inputs driven by advanced manufacturing, computing and large-scale infrastructure. This demand profile favors systems that can deliver steady output at scale. By producing fuels and hydrogen alongside solid carbon products, the company is aligning its model with sectors that require both energy and materials, including refining, transportation and heavy industry.

The environmental outcomes of the process are addressed as a function of its design rather than its primary objective. The company notes that FASForm operates as a closed-loop system that captures and repurposes byproducts, resulting in zero waste and significantly reduced emissions compared to conventional coal combustion. Sulfur and other compounds are removed during processing and converted into usable products, further reinforcing the idea that the process is built around maximizing value rather than managing waste. In this context, efficiency and emissions improvements emerge as direct consequences of a more complete utilization of the feedstock.

Frontieras’s initial project is the first step in a broader expansion strategy. The company anticipates replicating its model in multiple locations, particularly in regions where coal resources and industrial demand intersect. This suggests a scalable platform rather than a single-site operation, with the potential to establish a network of facilities that collectively redefine how coal is used in the modern economy.

By focusing on what coal can produce rather than how it has traditionally been used, Frontieras North America is articulating a distinct position within the energy and industrial landscape. As the company moves from concept to construction and eventually to operation, it is positioning itself as a developer of integrated energy and materials systems built on one of the world’s most abundant resources.

For more information, visit www.Frontieras.com.  

NOTE TO INVESTORS: The latest news and updates relating to Frontieras are available in the company’s newsroom at https://ibn.fm/Frontieras